Tirzepatide

Background

Tirzepatide is a synthetic dual agonist of the glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors, developed as a once‑weekly subcutaneous peptide therapeutic for type 2 diabetes mellitus (T2DM) and obesity.[12][14] It is a 39–amino acid linear peptide engineered on the backbone of native human GIP, with 19 amino acids shared with GIP and additional modifications to confer GLP‑1 receptor activity and prolonged half‑life.[15] A C20 fatty diacid side chain is attached via a hydrophilic linker to lysine at position 20, enabling high‑affinity albumin binding and extended circulation time suitable for weekly dosing.[15]

Tirzepatide was discovered and developed by Eli Lilly as the first “twincretin” or dual incretin receptor agonist, based on the concept that simultaneous activation of GIP and GLP‑1 receptors could produce superior metabolic benefits compared with selective GLP‑1 receptor agonism.[12][14] The drug has been commercialized in the United States as Mounjaro for T2DM and Zepbound for chronic weight management, with analogous approvals in other regions.[11][14]

Mechanism of action

Tirzepatide acts as a biased agonist at both the GIP receptor (GIPR) and GLP‑1 receptor (GLP‑1R), with relatively higher potency at GIPR and partial agonism at GLP‑1R compared with native GLP‑1.[12][14] Incretin hormones GIP and GLP‑1 are secreted post‑prandially from enteroendocrine K and L cells, respectively, and augment glucose‑dependent insulin secretion from pancreatic β‑cells.[12]

Key mechanistic features include:

• Pancreatic effects:

  • Enhanced glucose‑dependent insulin secretion via GIPR and GLP‑1R on β‑cells.[12][14]
  • Reduction in inappropriate glucagon secretion during hyperglycemia, although GIP can preserve glucagon responses under hypoglycemic conditions.[12][15]
  • Potential promotion of β‑cell function and mass in preclinical models.[12]

• Central and gastrointestinal effects:

  • GLP‑1R–mediated reduction in appetite and caloric intake via hypothalamic pathways.[12][14]
  • Delayed gastric emptying, particularly after initial doses, contributing to post‑prandial glucose control.[14]

• Adipose and metabolic effects:

  • GIPR activation in adipose tissue may enhance lipid handling and promote weight loss when combined with GLP‑1R agonism, despite the historically obesogenic reputation of GIP in some contexts.[12]
  • Clinical data show improvements in blood pressure, LDL cholesterol, and triglycerides, indicating broad cardiometabolic benefits.[14]

Compared with selective GLP‑1 receptor agonists such as semaglutide, tirzepatide produces larger reductions in HbA1c and body weight, supporting the therapeutic value of dual GIP/GLP‑1 receptor modulation.[14][15]

Evidence summary

Preclinical evidence

Preclinical studies in rodents and non‑human primates demonstrated robust reductions in fasting and post‑prandial glucose, body weight, and food intake, along with improvements in insulin sensitivity and lipid profiles.[12][14] Dual agonism was associated with greater efficacy than either GIP or GLP‑1 mono‑agonism at comparable exposure.[12]

Phase 3 type 2 diabetes program (SURPASS)

The SURPASS clinical development program evaluated tirzepatide across multiple settings in T2DM.[14]

• SURPASS‑1: Monotherapy vs placebo in patients with T2DM inadequately controlled with diet and exercise (n≈478; tirzepatide 5, 10, 15 mg once weekly vs placebo for 40 weeks).[14]

  • Mean HbA1c reductions up to approximately −2.1% to −2.4% from baseline at higher doses.[14]
  • Body‑weight reductions up to about −9 kg.[14]

• SURPASS‑2: Comparison with once‑weekly semaglutide 1 mg in patients on metformin (n≈1,879; tirzepatide 5, 10, 15 mg vs semaglutide 1 mg for 40 weeks).[14][15]

  • Tirzepatide was superior to semaglutide for HbA1c reduction, achieving mean decreases up to approximately −2.3% to −2.4% vs −1.9% with semaglutide.[14][15]
  • Weight loss reached ~11–12 kg at the 15 mg dose versus ~6–7 kg with semaglutide 1 mg.[14][15]

• SURPASS‑3 and SURPASS‑4: Compared tirzepatide with basal insulin (insulin degludec or insulin glargine) in patients with T2DM inadequately controlled on oral agents (sample sizes each in the ~1,900–2,000 range).[14]

  • Tirzepatide produced greater HbA1c reductions and substantial weight loss, whereas basal insulin was associated with weight gain.[14]
  • Lower rates of hypoglycemia were observed with tirzepatide relative to insulin.[14]

• SURPASS‑5: Add‑on to insulin glargine in T2DM (n≈475).[14]

  • Additional HbA1c reductions of approximately −2.0% with tirzepatide plus basal insulin, along with weight loss compared with weight gain in placebo plus insulin.[14]

A systematic review of tirzepatide clinical data concluded that the agent consistently produced HbA1c reductions >2% and body‑weight decreases exceeding 10–15% across several phase 3 studies, with glycemic efficacy and weight loss superior to most available GLP‑1 receptor agonists.[14]

Obesity/weight‑management trials (SURMOUNT)

Tirzepatide has been evaluated for chronic weight management in individuals with obesity or overweight, with or without T2DM.

• In the SURMOUNT‑1 phase 3 trial (adults with obesity or overweight without diabetes; n≈2,539), once‑weekly tirzepatide 5, 10, or 15 mg for 72 weeks produced mean weight reductions of about 15–21% of baseline body weight, significantly greater than placebo.[11][14]
• Additional trials in people with obesity and T2DM also showed marked weight loss, though absolute percentage reductions were somewhat smaller than in non‑diabetic populations.[11]

A narrative review of obesity trials characterized tirzepatide’s weight‑loss effect as comparable to or exceeding results of bariatric surgery in some cohorts, while acknowledging the need for longer‑term safety and durability data.[11]

Clinical and research uses

Approved indications

• Type 2 diabetes mellitus (T2DM): Tirzepatide is approved in the United States and multiple other jurisdictions as Mounjaro for improving glycemic control in adults with T2DM, typically as an adjunct to diet and exercise.[14]
• Chronic weight management (obesity/overweight): Under the trade name Zepbound, tirzepatide is approved by the U.S. Food and Drug Administration for chronic weight management in adults with obesity (body mass index [BMI] ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight‑related comorbidity, in combination with reduced‑calorie diet and increased physical activity.[11]

Investigational and off‑label applications

Research and early‑phase trials are exploring tirzepatide in additional metabolic and cardiometabolic contexts, including:

• T2DM with high cardiovascular risk, to assess major adverse cardiovascular event (MACE) outcomes.[14]
• Non‑alcoholic fatty liver disease/non‑alcoholic steatohepatitis (NAFLD/NASH), based on favorable effects on weight, glycemia, and lipids.[14]
• Potential broader cardiometabolic risk reduction in high‑risk populations.[11]

As of current evidence, these applications remain investigational, with no established regulatory approvals beyond T2DM and obesity/overweight.

Dosing context

Tirzepatide is administered as a once‑weekly subcutaneous injection using a prefilled, single‑dose pen device.[14][15] The molecule’s half‑life of approximately 5 days (reported in pharmacokinetic studies) supports weekly dosing.[14]

In phase 3 trials, dosing followed a gradual titration scheme to mitigate gastrointestinal adverse effects:

• Initiation at a low weekly dose, with stepwise escalation every 4 weeks to reach maintenance doses of 5 mg, 10 mg, or 15 mg once weekly, depending on tolerability and glycemic/weight targets.[14][15]

Dose regimens in clinical studies varied slightly by protocol and indication, but the 5–15 mg once‑weekly range is consistently reported across the SURPASS and SURMOUNT programs.[11][14][15] Dosing adjustments relative to renal or hepatic impairment have been limited in trials; more detailed recommendations are provided in product labels and regulatory documents, and usage must adhere to approved prescribing information.

Safety profile

Across T2DM and obesity trials, tirzepatide has demonstrated a safety profile broadly similar to GLP‑1 receptor agonists, with gastrointestinal events predominating.[11][14][15]

Common adverse effects

• Gastrointestinal: Nausea, vomiting, diarrhea, decreased appetite, constipation, and dyspepsia were the most frequently reported adverse events, typically mild to moderate and more common during dose escalation.[11][14][15]
• Injection‑site reactions: Mild local reactions were reported but rarely led to discontinuation.[14]
• Hypoglycemia: When used as monotherapy or added to metformin, clinically significant hypoglycemia was uncommon; risk increased when combined with insulin or sulfonylureas, similar to other incretin‑based therapies.[14]

Serious and less common risks

• Pancreatitis: As with GLP‑1 receptor agonists, cases of acute pancreatitis have been reported; causal attribution remains uncertain, but product information typically includes a warning and recommends discontinuation if pancreatitis is suspected.[12][14]
• Gallbladder disease: Weight‑loss–associated increases in cholelithiasis and cholecystitis have been observed in incretin‑based therapies; similar monitoring is recommended with tirzepatide.[11][14]
• Thyroid C‑cell tumors (animal data): In rodent studies, long‑acting incretin agonists, including tirzepatide, have been associated with C‑cell hyperplasia and medullary thyroid carcinoma; the relevance to humans is unknown, but this class effect underpins a boxed warning and specific contraindications.[14]
• Cardiovascular parameters: Modest reductions in blood pressure and improvements in lipids are typical; heart rate increases similar to those seen with GLP‑1 RAs have been reported but have not translated into clear adverse cardiovascular signals in available data.[14]

Long‑term safety beyond several years of exposure is not yet fully characterized, and dedicated cardiovascular outcome trials and post‑marketing surveillance are ongoing.[14]

Contraindications and precautions

Based largely on class effects and regulatory labeling for tirzepatide and GLP‑1 receptor agonists:[11][14]

• Contraindications (class‑based):

  • Personal or family history of medullary thyroid carcinoma (MTC).
  • Patients with multiple endocrine neoplasia syndrome type 2 (MEN2).
  • Known serious hypersensitivity to tirzepatide or any of its excipients.

• Precautions:

  • History of pancreatitis.
  • Severe gastrointestinal disease, particularly severe gastroparesis.
  • Use with insulin or insulin secretagogues requires caution due to hypoglycemia risk.
  • Monitoring for gallbladder disease in the context of rapid weight loss.[11][14]

Clinical use must follow up‑to‑date product labeling and professional guidelines; evidence for use in pregnancy, lactation, and specific high‑risk groups remains limited.

Regulatory status

In the United States, tirzepatide is approved by the Food and Drug Administration (FDA) as:

• Mounjaro: Once‑weekly subcutaneous injection for adults with T2DM to improve glycemic control, as an adjunct to diet and exercise.[14]
• Zepbound: Once‑weekly subcutaneous injection for chronic weight management in adults with obesity or overweight with at least one weight‑related comorbidity.[11]

In the European Union and other regions, tirzepatide has similarly been authorized for the treatment of adults with T2DM inadequately controlled on existing therapy, with additional weight‑management indications being granted or under review depending on jurisdiction.[14]

Regulatory agencies continue to require post‑marketing studies, including cardiovascular outcome trials and long‑term safety evaluations, to further define the benefit–risk profile of tirzepatide across diverse patient populations.[14]